Orsini Pharmaceutical Services Expands Partnership with Ultragenyx to Provide Dojolvi ™ (Triheptanoin)
ELK GROVE VILLAGE, Ill., July 10, 2020 / PRNewswire / – Orsini Pharmaceutical Services (“Orsini”), a leading independent national specialty pharmacy specializing in rare and complicated disease patients, today announced that it has been selected by Ultragenyx Pharmaceutical Inc. as a pharmaceutical partner Specialist with limited distribution for Dojolvi ™ (triheptanoin). Dojolvi ™ is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long chain fatty acid oxidation disorders (LC-FAOD).
LC-FAOD is a group of autosomal recessive genetic disorders characterized by metabolic deficiencies in which the body is unable to convert long chain fatty acids into energy. The inability to produce energy from fat can lead to severe depletion of glucose in the body and serious complications, which can lead to hospitalizations or premature death. LC-FAOD is included in newborn screening panels in the United States and some European countries due to the risk of serious consequences, including early death in life. Other current treatment options for LC-FAOD include fasting avoidance, low fat / high carbohydrate diets, carnitine, and even carbonaceous medium chain triglyceride (MCT) oil, a medical food product. LC-FAOD affects approximately 2,000 to 3,500 children and adults in the United States.
Chairman and CEO of Orsini Mike fieri commented, “We are proud to expand our partnership with Ultragenyx and provide Dojolvi to people with LC-FAOD. High-reach care coordination and collaboration is the driving force behind our unique specialty pharmacy care model, and our LC-FAOD care team is focused on patient therapy. quickly and by providing personalized and compassionate care. ”
About Orsini Pharmaceutical Services
Providing comprehensive and compassionate patient care since 1987, Orsini is a leading independent specialty pharmacy focused on rare and complicated diseases. Orsini’s services enable patients, physicians, payers and manufacturers to improve care, simplify processes and achieve better results. Orsini’s high touch clinical model centers on therapy-specific care teams that provide personalized care to patients based on their specific complex and chronic conditions and problems. The company’s comprehensive solutions include medication adherence programs, data analytics, custom manufacturer programs, and nationwide nursing coverage for required home infusion services. Orsini delivers specialty drugs nationwide and has several limited and exclusive distribution contracts with manufacturers. Based at Elk Grove Village, IL, Orsini is accredited with ACCH, JCAHO, URAC and NABP.
For more information on Orsini’s services, contact us at 847-734-7373 ext. 545, write to us at [email protected], or visit www.orsinihealthcare.com.
For more information on Dojolvi, please see Complete prescribing information.
SOURCE Orsini Healthcare